Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03 mai 2022 09h17 HE
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections
07 oct. 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company’s Acuitas® AMR Gene Panel and...
OpGen Provides update on Curetis Group’s R&D Collaboration
18 sept. 2019 07h30 HE
|
OpGen, Inc.
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
13 juin 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software will be presented at ASM...
OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
14 mai 2019 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance...
Global charity discovers superbugs in pork products
19 déc. 2018 08h00 HE
|
World Animal Protection
Toronto, ON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Bacteria that is resistant to antibiotics most critically important to humans, has been found in pork from supermarket shelves in Brazil, Spain and...
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
06 déc. 2018 03h30 HE
|
SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
14 juin 2016 12h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
19 mai 2015 16h00 HE
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
09 avr. 2015 12h02 HE
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...